Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reissued by Wedbush in a research report issued to clients and investors on Tuesday,RTT News reports. They presently have a $25.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 183.13% from the stock’s current price.

ITOS has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research note on Monday, September 16th. JPMorgan Chase & Co. cut their price objective on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, Wells Fargo & Company began coverage on shares of iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price for the company.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $8.83 on Tuesday. iTeos Therapeutics has a 12-month low of $8.41 and a 12-month high of $18.75. The stock’s 50 day simple moving average is $10.69 and its 200 day simple moving average is $14.06.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ITOS. Vanguard Group Inc. lifted its holdings in iTeos Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock worth $20,468,000 after purchasing an additional 9,660 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of iTeos Therapeutics in the 1st quarter worth approximately $3,337,000. Public Employees Retirement System of Ohio lifted its stake in shares of iTeos Therapeutics by 4.9% in the 1st quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after acquiring an additional 1,817 shares during the period. Kennedy Capital Management LLC bought a new position in shares of iTeos Therapeutics in the first quarter valued at approximately $1,988,000. Finally, Bank of New York Mellon Corp increased its stake in shares of iTeos Therapeutics by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 121,250 shares of the company’s stock valued at $1,799,000 after acquiring an additional 5,409 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.